Cytokine release syndrome

Cytokine Release Syndrome: Clinical Aspects and Management

Illustration of the mechanism of Cytokine Release Syndrome

Cytokine Release Syndrome (CRS) is a significant medical condition that can occur after the therapeutic infusion of antibodies. It is characterized by a set of symptoms resulting from the rapid release of cytokines by cells targeted by these antibodies.

Definition and Symptoms

CRS is a systemic inflammatory response marked by the release of a large number of cytokines. Common symptoms include nausea, headache, tachycardia, hypotension, rash, and shortness of breath.

Causes and Pathophysiology

Immunotherapy leading to CRS

CRS is often triggered by immunotherapies, such as chimeric antigen receptor (CAR) T-cell therapy, which involve the infusion of antibodies. The antibodies target specific cells, leading to their activation and the subsequent release of cytokines.

Severity and Risks

While most patients experience mild to moderate symptoms, CRS can sometimes escalate to severe and life-threatening levels. The severity depends on various factors, including the type of immunotherapy and the patient's overall health.

Diagnosis

Diagnosis of CRS is primarily based on clinical symptoms and the timing of their appearance after antibody therapy. Laboratory tests can support the diagnosis by showing elevated levels of cytokines.

Treatment and Management

Treatment of CRS is tailored to the severity of the symptoms. Mild cases may require symptomatic treatment, while severe cases might necessitate hospitalization and administration of corticosteroids or tocilizumab, a medication that blocks the cytokine interleukin-6.

Prevention Strategies

Preventive strategies in high-risk patients include dose modifications and premedication. Ongoing research aims to develop approaches to mitigate CRS while preserving the efficacy of antibody therapies.

Implications in Cancer Therapy

CRS is particularly relevant in the context of cancer therapy, where novel treatments like CAR T-cell therapy have shown promising results but also carry the risk of CRS.

See Also

• Chimeric antigen receptor T-cell therapy
• Immunotherapy
• Cytokines

References

<references>

• National Center for Biotechnology Information - Cytokine Release Syndrome.
• National Cancer Institute - CAR T-Cell Therapies.

</references>

External Links

• National Cancer Institute - Information on CAR T-Cell Therapy
• American Society of Hematology - Managing CRS in CAR T-Cell Therapy

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia